CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 500 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CLK1/4-IN-1
<p>CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.</p>Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81CDK4/6-IN-24
CAS:<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Fórmula:C32H41N7O3Cor e Forma:SolidPeso molecular:571.713Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47Cdc7-IN-11
CAS:<p>Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.</p>Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384CDK2-IN-30
CAS:<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Fórmula:C18H25N7O3SCor e Forma:SolidPeso molecular:419.50CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Fórmula:C21H22N4OCor e Forma:SolidPeso molecular:346.43CDDD11-8
CAS:<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Fórmula:C24H26N6Cor e Forma:SolidPeso molecular:398.50CDK2-IN-39
CAS:<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Fórmula:C14H15N3O4SCor e Forma:SolidPeso molecular:321.352CDK4/9-IN-1
CAS:<p>CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.</p>Fórmula:C22H34N6O2Cor e Forma:SolidPeso molecular:414.544P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Fórmula:C20H15FN4O2Cor e Forma:SolidPeso molecular:362.357DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49CTX-712
CAS:<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Fórmula:C19H17FN8O2Cor e Forma:SolidPeso molecular:408.39CDK7/12-IN-1
CAS:<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28CDK7-IN-17
CAS:<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Fórmula:C24H26F3N6OPCor e Forma:SolidPeso molecular:502.47CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Cor e Forma:SolidPeso molecular:359.355
